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Tubulointerstitial renal fibrosis is a chronic disease process affecting chronic kidney
disease (CKD). While the etiological role of transforming growth factor-beta (TGF-β)
is well known for epithelial–mesenchymal transition (EMT) in chronic kidney
disease, effective therapeutics for renal fibrosis are largely limited. As a member
of the TGF-β superfamily, bone morphogenetic protein-7 (BMP-7) plays an
important role as an endogenous antagonist of TGF-β, inhibiting fibrotic
progression in many organs. However, soluble rhBMP-7 is hardly available for
therapeutics due to its limited pharmacodynamic profile and rapid clearance in
clinical settings. In this study, we have developed a novel therapeutic approach
with protein transduction domain (PTD) fused BMP-7 in micelle (mPTD-BMP-7) for
long-range signaling in vivo. Contrary to rhBMP-7 targeting its cognate receptors,
the nano-sized mPTD-BMP-7 is transduced into cells through an endosomal
pathway and secreted to the exosome having active BMP-7. Further,
transduced mPTD-BMP-7 successfully activates SMAD1/5/8 and inhibits the
TGF-β–mediated epithelial–mesenchymal transition process in vitro and in an in
vivo unilateral ureter obstruction model. To determine the clinical relevance of our
strategy, we also developed an intra-arterial administration of mPTD-BMP-7
through renal artery in pigs. Interestingly, mPTD-BMP-7 through renal artery
intervention effectively delivered into Bowman’s space and inhibits unilateral
ureter obstruction–induced renal fibrosis in pigs. Our results provide a novel
therapeutic targeting TGF-β–mediated renal fibrosis and other organs as well as
a clinically available approach for kidney.
Keywords: micellized protein transduction domain-bone morphogenetic protein-7, renal fibrosis,






Capital Medical University, China
Piye Niu,
Capital Medical University, China
Paul J. Higgins,








†These authors have contributed
equally to this work.
Specialty section:
This article was submitted to
Inflammation Pharmacology,
a section of the journal
Frontiers in Pharmacology
Received: 04 August 2020
Accepted: 09 October 2020
Published: 19 November 2020
Citation:
Kim S, Jeong C-H, Song SH, Um JE,
Kim HS, Yun JS, Han D, Cho ES, Nam
BY, Yook JI, Ku M, Yang J, Kim M-D,
Kim NH and Yoo T-H (2020) Micellized
Protein Transduction Domain-Bone
Morphogenetic Protein-7 Efficiently






Frontiers in Pharmacology | www.frontiersin.org November 2020 | Volume 11 | Article 5912751
TECHNOLOGY AND CODE
published: 19 November 2020
doi: 10.3389/fphar.2020.591275
INTRODUCTION
Chronic kidney disease (CKD) is a serious health problem
resulting from congenital abnormalities and chronic renal
injury, and for which effective therapeutics are currently
lacking (Bikbov et al., 2018). Renal fibrosis is the hallmark of
progressive kidney injury, characterized by a tubule-interstitial
fibrosis and glomerulosclerosis. Regardless of primary causes,
CKD manifested as progressive renal fibrosis results in
epithelial–mesenchymal transition (EMT) of tubules and
glomeruli and subsequent extracellular matrix deposition.
Activation of transforming growth factor-beta (TGF-β) is a
well-known EMT inducer of renal fibrosis (Meng et al., 2015).
While bone morphogenetic protein-7 (BMP-7) has been
studied for bone regeneration, it is now drawing great
attention as a therapeutic for fibrotic diseases, including renal
fibrosis. BMP-7 not only counteracts TGF-β signaling–mediated
EMT via activation of SMAD1/5/8 but is also critically involved in
kidney morphogenesis and development (Godin et al., 1998;
Manson et al., 2015). Interestingly, mice embryos lacking
BMP-7 exhibit defective kidney and eye development,
indicating the importance of BMP-7 in the physiological
function of kidney (Dudley et al., 1995; Jena et al., 1997).
Although the effectiveness of BMP-7 for fibrosis was
recognized 2 decades ago, BMP-7 therapeutics are largely
lacking due to pharmacodynamic limitations, particularly in
clinical settings. Animal studies have revealed that current
soluble rhBMPs exhibit a half-life of 7–16 min in nonhuman
primate due to rapid clearance and enzymatic degradation (Lo
et al., 2012), necessitating an excess dose with initial burst release
of rhBMP. Efficient drug delivery into kidney poses another
obstacle in the clinical application of current rhBMP-7.
Recently, we have developed a pro-drug BMP-7 having novel
mode of action fused with protein transduction domain (PTD)
(Kim et al., 2014). While rhBMPs directly bind to cognate
receptors, the prodrug is designed for endosomal transduction
into cells (Vendeville et al., 2004; Wadia et al., 2004), and
subsequent intracellular activation into active BMPs.
Nevertheless, PTD-mediated cellular delivery faces several
hurdles due to the limited size of hydrophobic cargos (less
than 10 kd) and endosomal rescues (Kabouridis, 2003). In this
study, we have developed micellized PTD-BMP-7 (mPTD-BMP-
7) to enhance therapeutic application of PTD for CKD. mPTD-
BMP-7 is successfully transduced into the endosomes and
counteracts the TGF-β–mediated EMT process via activation
of SMAD1/5/8. For clinical relevance, we have also developed
interventional administration through renal artery in a pig
unilateral ureter obstruction (UUO) model.
RESULTS
Developmental Strategy and Preparation of
Micellized Protein Transduction
Domain-Bone Morphogenetic Protein-7
During the biogenesis of endogenous BMP-7, the prodomain of
BMP-7 is cleaved by the subtilisin-like proprotein convertase
family, a latent form of BMP-7 being secreted (Constam and
Robertson, 1999). In this process, latent BMP-7 complex interacts
with the N-terminal of fibrillin-1 (FBN1) microfibrils in the
extracellular matrix (Gregory et al., 2005). While the rhBMPs
only consist of dimeric active BMP, we have previously reported
that denatured prodrug BMPs including prodomain were
functional in vivo (Figure 1A). To increase the transduction
efficiency of large cargo (i.e., 55 kd in PTD-BMP-7), we prepared
mPTD-BMP-7. The typical particle size of the PTD-BMP-7 in
micelle was ∼200 nm as measured by direct light scattering and
scanning electron microscope (Figure 1B).
Endosomal Transduction of Micellized
Protein Transduction Domain-Bone
Morphogenetic Protein-7 and Exosomal
Secretion of Active Bone Morphogenetic
Protein-7
To examine intracellular transduction of mPTD-BMP-7, we
treated mPTD-BMP-7 into 293A cells and examined the
transduction by immunofluorescence and Western blot
analysis in Triton-insoluble fraction because denatured PTD-
BMP-7 forms insoluble aggregate in the micelle. As shown in
Figure 2A, mPTD-BMP7 was successfully transduced into the
cells in a time-dependent manner. Notably, mPTD-BMP-7 was
continuously transduced into the cells for up to 16 h. Confocal
microscopy with Z-stack sections also revealed that mPTD-BMP-
7 was successfully transduced into the cytosolic space. Because the
PTD-mediated protein delivery was mediated by endosomal
pathway (Vendeville et al., 2004; Wadia et al., 2004), we
labeled the PTD-BMP-7 with fluorescent dye and examined
the intracellular localization with endosomal Rab7 (Ras
superfamily of small G protein) GTPase. Indeed, transduced
mPTD-BMP-7 was tightly co-localized with Rab7 in the
cytosolic space (Figure 2B). To further examine the
membrane-coated transduction, we labeled the PTD-BMP-7
with uranyl acetate and examined it with a transmission
electron microscope. Interestingly, PTD-BMP-7 was
internalized within membrane-coated intracellular vesicles and
successfully transported into the Golgi apparatus (Figure 2C).
These results indicate that mPTD-BMP-7 was actively transduced
with endosomal pathway and transported into the trans-Golgi
network.
Next, we examinedwhether transducedmPTD-BMP-7 is secreted
to extracellular space. Because prodomain in latent BMP-7 tightly
binds to FBN-1 for extracellular secretion (Gregory et al., 2005;Wohl
et al., 2016), we cloned flag-tagged N-terminal of FBN1 expression
vector and expressed it in 293A cells. After incubation of mPTD-
BMP-7 tagged with HA in the C-terminus of BMP-7 into FBN1
expressing cells, we harvested the culture supernatant and performed
immunoblot analysis. Indeed, ∼15 kd-sized active BMP-7 bands were
detected compared to control (Figure 2D). When we
immunoprecipitated the supernatant with FBN1, immunoblot
analysis revealed that secreted BMP-7 had interacted with FBN1.
Given the endosomal transduction of mPTD-BMP-7, we next
collected extracellular vesicles (exosomes) and examined the
secreted BMP-7. Interestingly, active BMP-7 and FBN1 were
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clearly detected in secreted exosomes (Figure 2E). Notably,
unprocessed PTD-BMP-7 was detected in extracellular vesicles,
indicating an endosomal–exosomal recycling of mPTD-BMP-7.
Examining the cytotoxicity of mPTD-BMP-7, we found that
mPTD-BMP-7 is not cytotoxic under excess dose exposure
in vitro (Figure 2F). These results indicate that transduced
mPTD-BMP-7 via endosomal pathway was successfully processed





Mesenchymal Transition Via Activation
of SMAD1/5/8
BMP-7 immediately elicits phosphorylation of SMAD1/5/8 to
counteract TGF-β signal (Wadia et al., 2004). To test whether
mPTD-BMP-7 affects SMAD1/5/8 activation, we treated 100 ng
of mPTD-BMP-7 and examined the phosphorylation status of
SMAD1/5/8 in A549 cells. Immunoblot and immunofluorescence
study revealed thatmPTD-BMP-7 increased phosphorylation and its
nuclear translocation of SMAD1/5/8 (Figure 3A). Because Noggin
specifically binds and antagonizes active BMP-7 (Groppe et al.,
2002), we next overexpressed Noggin and treated mPTD-BMP-7
to examine SMAD1/5/8 activation (Figure 3B). Indeed, mPTD-
BMP-7 did not activate SMAD1/5/8 in the presence of Noggin. In
TGF-ß–responsive A549 cells, the plasminogen activator inhibitor-1
(PAI-1, SERPINE1) is the typical target gene of TGF-β. When we
examined the effect of mPTD-BMP-7 on TGF-β–mediated PAI-1
activation, TGF-β–activated PAI-1 transcription and the treatment of
mPTD-BMP-7 suppressed PAI-1 transcript abundance induced by
TGF-β (Figure 3C). Importantly, this inhibitory action counteracting
TGF-β was completely abolished by the treatment of neutralizing
BMP-7 antibody, indicating that mPTD-BMP-7 was successfully
processed into active BMP-7 resulting in inhibition of TGF-ß.
FIGURE 1 | Schematic diagram and preparation of micellized PTD-BMP-7. (A) Schematic diagram of biogenesis of latent bone morphogenetic protein-7 (BMP-7)
(upper), and developmental strategy of micellized PTD-BMP-7 compared to soluble rhBMP-7 (lower). (B) Particle size distribution detected by direct light scattering
(left) and scanning electron microscopy (right). Scale bar, 200 nm.
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FIGURE 2 | Endosomal transduction of micellized PTD-BMP-7 (mPTD-BMP-7) and exosomal secretion of bone morphogenetic protein-7 (BMP-7). (A) HEK 293 cells
were treated with 200 ng of mPTD-BMP-7 for the indicated period, and the insoluble fraction of whole cell lysates were subjected to immunoblot analysis with anti-HA
antibody (left). Arrow and arrowhead denote monomeric and aggregated PTD-BMP-7, respectively. The 293 cells were treated with 200 ng of mPTD-BMP-7, and
intracellular transductionwasmonitored by confocalmicroscopy (right). Z-stack in blow. Scale bar, 5 μm. (B) The 293Acells were transiently transfectedwithmCherry-
tagged Rab7 and treated with 200 ng of HA-tagged mPTD-BMP-7 for 3 h. Intracellular localization was observed with confocal microscopy and Nuc-blue served as nuclear
staining of live cell imaging. (C) The 293 cells were treated with 200 ngmPTD-BMP-7, and the cells were subjected to transmission electronmicroscopy. Note a membrane-
coated mPTD-BMP-7 in endosomes (middle) and Golgi (right). (D) The 293 cells were transfected with flag-tagged N-terminal of fibrillin-1 (FBN-1) and treated with 500 ng
HA-tagged mPTD-BMP-7 for 16 h. The culture medium was harvested and subjected for immunoblot analysis (left) and immunoprecipitation with anti-flag (FBN-1). Arrows
indicate active BMP-7. (E) Exosomal secretion of active BMP-7 (arrow) andmPTD-BMP-7 (arrow head) with FNB-1. CD63 serves as exosomal marker. (F)Cellular toxicity of
mPTD-BMP-7. The 293A cells were incubated in various concentrations of mPTD-BMP-7, and cell growth was monitored by JuLi real-time live cell analyzer (NanoEntek).
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To examine the effects of mPTD-BMP7 on EMT related to
renal fibrosis, mouse inner medullary collecting duct (IMCD)
cells were incubated with mPTD-BMP-7 and examined for
intracellular transduction. As with the 293A cells, mPTD-
BMP-7 was successfully transduced into the IMCD cells
(Figure 3D) with activation of SMAD1/5/8 (Figure 3E).
To determine the effect of mPTD-BMP-7 in TGF-
β–mediated EMT, we treated TGF-β in combination with
mPTD-BMP-7 and examined EMT markers in IMCD
cells. The TGF-β treatment increased expression of
typical mesenchymal genes including fibronectin, type I
collagen, and α-smooth muscle actin, while mPTD-BMP-7
largely blocked TGF-β–mediated EMT (Figure 3F). Those
protein expressions of mesenchymal markers were closely
correlated to the transcript abundance (Figure 3G).
These results indicate that mPTD-BMP-7 inhibits the
TGF-β–mediated EMT process by the activation of
SMAD1/5/8.
FIGURE 3 | Micellized PTD-BMP-7 (mPTD-BMP-7) antagonizes transforming growth factor-beta (TGF-β)–mediated epithelial–mesenchymal transition (EMT) via
activation of SMAD1/5/8. (A) 293A cells were treated with 100 ng of mPTD-BMP-7 and activation of SMAD1/5/8 were detected by immunoblot analysis (left) and
immunofluorescence (right). (B) The 293 cells transfected with control or Noggin expression vector were treated with mPTD-BMP-7, and SMAD1/5/8 phosphorylation
was detected by immunoblot analysis. (C)mPTD-BMP-7 inhibits PAI-1 transactivation induced by TGF-β. A549 cells were incubated TGF-β (5 ng) with or without
mPTD-BMP-7 for 16 h, and PAI-1 transcript abundance was detected by qRT-PCR (white). Neutralizing antibody against soluble BMP-7 abolished the effect of mPTD-
BMP-7 (gray). qPCR was performed from triplicate experiment. (D) Intracellular transduction of mPTD-BMP-7 was detected by immunofluorescence in inner medullary
collecting duct (IMCD) cells. Scale bar, 20 μm. (E) IMCD cells were treated with 100 ng of mPTD-BMP-7 and activation of SMAD1/5/8 were detected by Western blot
analysis. (F,G) IMCD cells were treated with vehicle or mPTD-BMP-7 (200 ng) or TGF-β (5 ng) or combination for 3 days, and cell lysates were subjected for immunoblot
analysis of fibronectin, type I collagen, and α-smooth muscle actin (E). Quantitation of transcript (upper) and protein (lower) abundance of mesenchymal markers in IMCD
cells, ***p < 0.001 vs. Vehicle; #p < 0.05 vs. TGF-β; ##p < 0.01 vs. TGF-β; ###p < 0.001 vs. TGF-β (F).
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Effect of Micellized Protein Transduction
Domain-Bone Morphogenetic Protein-7 on
the Unilateral Ureteral Obstruction Renal
Fibrosis Model
UUO is a well-established model for renal fibrosis, given the
pivotal role of TGF-β signaling during UUO-induced EMT
(Miyajima et al., 2000; Ma et al., 2003). To determine the anti-
fibrotic effect of mPTD-BMP-7 in vivo, we designed a mouse
UUO model using intraurethral injection of mPTD-BMP-7
(Figure 4A). Masson’s trichrome and immunohistochemistry
revealed that the UUO induced severe tubule-interstitial
fibrosis, while the intraurethral injection of mPTD-BMP-7
reduced UUO-induced renal fibrosis (Figure 4B).
Immunohistochemistry showed that fibronectin and α-smooth
muscle actin specifically deposited in the interstitial space of
kidney by UUO and mPTD-BMP-7 largely decreased interstitial
fibronectin and α-smooth muscle actin. To quantitate
mesenchymal markers, we examined protein and transcript
abundances in mouse kidney samples. Consistently, both
mRNA and protein abundances of mesenchymal genes were
significantly increased by UUO, and the EMT progression was
relieved by mPTD-BMP-7 injection (Figure 4C). Multiple
isoforms due to the alternative splicing of fibronectin and type
I collagen were increased by UUO, and all isoforms were
suppressed by the treatment of mPTD-BMP-7. Although
intraurethral injection was effective in mouse model,
pharmacologic approach via urethra is very limited in human.
To determine the route of administration for clinical application,
we next examined therapeutic effects of mPTD-BMP-7 by
repeated intravenous injection in the mouse UUO model.
However, we found the therapeutic potential of mPTD-BMP-7
disappointing with intravenous administration in the UUO
model, probably due to limited delivery into the kidney
(Supplementary Figure S1). These results suggest that a
different route of administration of mPTD-BMP-7 is required
for kidney.
Application of Micellized Protein
Transduction Domain-Bone Morphogenetic
Protein-7 by Angiography on Unilateral
Ureter Obstruction–Induced Renal Fibrosis
Model
Recently, vascular intervention under image guidance has rapidly
expanded to treat specific organs. We attempted to deliver
FIGURE 4 |Micellized PTD-BMP-7 (mPTD-BMP-7) attenuates renal fibrosis in mouse unilateral ureter obstruction (UUO) model. (A) Schematic diagram for mouse
UUO experiment with intra-ureteral injection of mPTD-BMP-7. (B)Masson’s trichrome stain and immunohistochemical staining of fibronectin and α-smooth muscle actin
in UUO kidneys. (C) Immunoblot analysis for mesenchymal markers in mouse UUO kidney (left) and quantitative data (right). ***p < 0.001 vs. Vehicle-Sham; ###p <
0.001 vs. Vehicle-UUO.
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mPTD-BMP-7 by catheter-directed intra-arterial administration
into pig kidney through renal artery. We found that this provides
a novel route of administration to deliver mPTD-BMP-7 into the
pig kidney (Figure 5A). To determine the delivery potential of
renal arterial intervention, we labeled PTD-BMP-7 with ICG and
formulated in micelle. To administrate for a sufficient period, the
ICG-labeled mPTD-BMP-7 (100 μg) was diluted in saline
(100 ml) and injected into the renal artery with a 2.1 F
microcatheter for 2 h period. After 3 h intra-arterial
administration of mPTD-BMP-7, the pig was sacrificed and
FIGURE 5 | Interventional administration of micellized PTD-BMP-7 (mPTD-BMP-7) via renal artery attenuates renal fibrosis in pig unilateral ureter obstruction. (A)
Renal angiography after insertion of micro-catheter into renal artery. (B) ICG-labeled mPTD-BMP-7 was serially diluted with PBS for fluorescence quantitation (upper).
Gross (middle) and fluorescence (lower) images of pig kidney administrated vehicle or mPTD-BMP-7. The pig kidneys were divided into half by longitudinal sections for
inner medullary (left) and outer cortical (right) areas. (C) Immunohistochemical staining of pig kidney using polyclonal antibody against prodomain of bone
morphogenetic protein-7. Note the increased expression level of bone morphogenetic protein-7 in proximal tubules andmultiple granule-like foci in the Bowman’s space
in mPTD-BMP7 administrated kidney (red circles). Scale bar, 20 μm. (D) Gross (upper left) and histologic (right) images of vehicle or mPTD-BMP-7 administrated pig
kidney. Black circles denote remaining glomerulus. The number of remaining glomeruli was counted in randomly selected 20 high power fields (lower left).
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the kidney was examined with an in vivo bioluminescent imaging
system to determine whether mPTD-BMP-7 was delivered into
pig kidney. Indeed, ICG-labeled mPTD-BMP-7 was successfully
delivered into the kidney parenchyma (Figure 5B). Notably, the
fluorescence intensity of the outer surface was stronger than the
inner medullar space, suggesting that mPTD-BMP-7 is mainly
delivered into the renal cortex, consisting of glomeruli and
tubules. Considering a depth limitation of fluorescence image,
more than 10 μg of mPTD-BMP-7 was delivered into the pig
kidney. To further determine renal distribution of mPTD-BMP-
7, we performed immunohistochemical staining with two
different antibodies to detect epitopes for prodomain and
active domains of BMP-7, respectively. Consistent with a
critical function of BMP-7 in kidney (Godin et al., 1998;
Gould et al., 2002; Tomita et al., 2013), endogenous BMP-7 is
highly expressed in kidney parenchyma, especially in proximal
tubules (Figure 5C; Supplementary Figure S2A). As both
antibodies detected BMP-7 similarly, expression levels of
BMP-7 in proximal tubules were increased in mPTD-BMP-7
treated kidney compared to vehicle. In particular, numerous
BMP-7–positive granule-like foci were clearly noted following
the administration of mPTD-BMP-7 in Bowman’s space and the
parietal layer of the glomerular capsule. Renal transduction of
mPTD-BMP-7 was also verified with Western blot analysis from
the pig kidney (Supplementary Figure S2B). These results
indicate that the interventional approach via renal artery
successfully delivered mPTD-BMP-7 to the kidney
parenchyma and that mPTD-BMP-7 is actively transported
from the glomerular capillaries to Bowman’s space and
proximal tubules, probably by endosomal uptake and
exosomal transport.
To examine whether the interventional approach is effective in
the UUO model, we next made a laparoscopic porcine UUO
model and administrated mPTD-BMP-7 to the kidney for 2 h
with the use of infusion set via the renal artery. After 1 week of
UUO surgery, the pig kidneys were examined grossly and
histologically (Figure 5E). Grossly in hemi-section, the
mPTD-BMP-7–treated kidney was less swollen and more
pinkish in color. Histologically, UUO induced severe
interstitial fibrosis with tubular atrophy, while the mPTD-
BMP-7 treatment decreased fibrosis and tubular atrophy.
Interestingly, the number of existing glomerulus in the UUO
kidney was increased by mPTD-BMP-7 administration
compared to control. To revalidate the porcine model with
intervention, we have performed repeated experiments and
obtained similar results (Supplementary Figure S2C).
DISCUSSION
Although the pivotal role of TGF-β–induced EMT in various
fibrotic diseases is well known, an effective therapeutic is still
lacking. Small molecule inhibitors and antibodies targeting TGF-β
receptors are under active development. For example,
Galunisertib targets kinase activity of TGF-β receptor I for
treating cancer (Huynh et al., 2019). Several antibodies
targeting ligand-receptor interaction have also been developed.
However, clinical application of those therapeutics for chronic
diseases is very limited due to on-target toxicities, such as cardiac
toxicity (de Gramont et al., 2017).
As a well-known endogenous TGF-β inhibitor, BMP-7
comprises an alternative approach against TGF-β–induced
fibrotic diseases including kidney (Zeisberg et al., 2003b;
Manson et al., 2015). While the TGF-β specifically induces and
binds to the extradomain-A isoform of fibronectin resulting in
myofibroblastic differentiation and α-smooth muscle actin
expression in UUO model (Serini et al., 1998; Yokoi et al.,
2004), mPTD-BMP-7 decreased all isoforms of fibronectin and
type I collagen. Further study is required to determine BMP-7’s
anti-fibrotic effect on extradomain-A fibronectin and thus
delineate the mechanistic link between TGF-β and BMP-7. In
addition to its effectiveness, BMP-7 therapeutics for fibrosis
provide long-term safety with excess dose, a significant clinical
advantage (Zeisberg et al., 2003a). In addition, transgenic
overexpression of systemic BMP-7, including kidney and liver,
was tolerable in mice with normal renal function up to 1 year
(Wang et al., 2006).
Similar to TGF-β, BMP-7 is generated from a precursor
polypeptide that is proteolytically cleaved, generating a homo-
dimeric N-terminal prodomain and disulfide-linked mature
dimer (Gregory et al., 2005; Robertson and Rifkin, 2016). The
prodomains carrying mature BMP-7 tightly interact with FBN1,
forming a latent BMP-7 which is secreted into extracellular space
and providing long-range signaling activities in vivo (Gregory
et al., 2005; Wohl et al., 2016). Although latent BMP-7 is largely
regarded as biologically inactive, the prodomain of the TGF-β
superfamily is critically required for the long-range action due to
its serving as a niche for growth factors, especially in clinical and
in vivo (Sengle et al., 2011; Sengle and Sakai, 2015). Interestingly,
active TGF-β and BMP-7 in the latent complex directly interact
with TGFBRII and BMPRII, respectively (Sengle et al., 2008;
Campbell et al., 2020). Furthermore, those latent TGF-β and
BMP-7 are biologically active without being released from the
prodomain by extracellular proteases (Sengle et al., 2008;
Campbell et al., 2020). While most in vitro and in vivo studies
have been conducted with rhBMP-7 without prodomain, the
bioavailability and physiological relevance of latent BMP-7 is not
well understood.
In this study, we designed a recombinant BMP-7 including
prodomain and formulated in micelle (mPTD-BMP-7) to
increase intracellular transduction and long-range signaling
activity in vivo. We found that mPTD-BMP-7 successfully
activates SMAD1/5/8 and inhibits TGF-β–induced PAI-1
transactivation. Noggin expression or neutralizing antibody
abolished those effects, indicating that active BMP-7 is being
secreted following the transduction of mPTD-BMP-7.
Importantly, mPTD-BMP-7 is transduced into the cells by
endosomal transport and secreted with FBN1 in exosomes.
The fluorescent-labeled exosomes injected into circulating
blood could secrete into the urine (Cheng et al., 2012).
Therefore, administration of mPTD-BMP-7 through renal
artery can be delivered into the Bowman’s space and collecting
tubules by exosomal transport.
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In conclusion, we report that prodrug BMP-7 provides an
alternative therapeutic against TGF-β–mediated fibrotic disease
with minimal toxicity. Furthermore, interventional delivery of
mPTD-BMP-7 via renal artery increased bioavailability into the
kidney. Further pharmacologic and preclinical studies are
required for clinical therapeutics for renal fibrosis.
MATERIALS AND METHODS
Cell Lines and Expression Vectors
HEK293, A549 cells (obtained from ATCC) and 293A cells
(Thermo Fisher) were routinely cultured in DMEM medium
containing 10% FBS. IMCD cells (a gift from professor JP Lee at
Boramae Hospital) were cultured in a DMEM/F12 medium with
10% FBS. Human Noggin and FBN-1 (a.a. 1–1,647) expression
vectors tagged with flag or 6× His were generated from cDNA of
293 cells. Fluorescence mCherry-tagged Rab7 expression vector
was kindly provided by S. Y. Kim (KNCC, Korea). The
transfection was performed by Lipofectamine 2000 according




The bacterial expression vectors for HA-tagged PTD-BMP-7 and
protein purification were described previously (Vendeville et al.,
2004; Wadia et al., 2004; Kim et al., 2014). The denatured
polypeptide was micellized with filtered 0.1% egg lecithin
(BOC Sciences) using bath sonication. For in vivo fluorescent
imaging, PTD-BMP-7 was labeled with ICG (ICG-sulfo-OSu,
Dojindo Molecular Technologies). Alternatively, PTD-BMP-7
was fluorescent labeled with the Alexa-Fluor-488 protein
labeling kit (Invitrogen) for immunofluorescence study. For
cellular transduction, mPTD-BMP-7 was directly treated into
the culture medium. Particle size of mPTD-BMP-7 was
determined by direct light scattering (ELSZ-200ZS, Otsuka
Electronics).
Western Blot Analysis and
Immunofluorescence
For the Western blot analyses, protein extracts were prepared in
Triton ×-100 lysis buffer. Antibodies against HA (901501,
BioLegend, 1:5,000), BMP-7 (ab84684, Abcam, 1:2,000),
SMAD1 (#9743S, Cell Signaling, 1:2,000), phospho-SMAD1/5/
8 (#13820, Cell Signaling, 1:2,000), CD63 (sc-5275, Santa Cruz, 1:
1,000), fibronectin (a0245, Dako, 1:5,000), type I collagen (1310-
01, SouthernBiotech, 1:500), alpha-smooth muscle actin (ab5694,
Abcam, 1:1,000), ß-actin (a5441, Sigma-Aldrich, 1:5,000), and
tubulin (LF-PA0146, AbFrontier, rabbit polyclonal, 1:5,000) were
obtained from commercial vendors. Protein abundance in
immunoblot analysis was quantitated by the publicly available
ImageJ program. For immunofluorescent analysis, the cells were
treated with mPTD-BMP for 16 h and intracellular transduction
of recombinant protein was detected against anti-HAmonoclonal
antibody and anti-mouse IgG-conjugated Alexa-Fluor-488
secondary antibody, as described previously (Kim et al., 2014).
The 293A cells were transfected with mCherry-Rab7 for a 48 h
period, and Alexa-488 tagged mPTD-BMP-7 was treated to cells
for 3 h followed by nuclear stain with NucBlue Probe (Thermo
Fisher, R37605) for live cell imaging. Cellular fluorescence was
monitored using confocal microscopy (Zeiss LSM780). Rabbit
polyclonal antibody detecting prodomain of BMP-7 was
generated by synthetic peptide (GLIGRHGPQNKQP) followed
by affinity purification (Labfrontier). Functional blocking of
secreted BMP-7 was performed by directly adding 10 µg/ml
neutralizing antibody against BMP-7 (MAB3542, R&D
Systems) to normal culture medium.
quantitative Polymerase Chain Reaction
and Primers
Total RNA was isolated using TRIzol reagent (Invitrogen)
following the manufacturer’s protocol. The SuperScript III
synthesis kit (Invitrogen) was used to generate cDNA. Real-
time quantitative PCR analysis was performed with an ABI-
7300 instrument under standard conditions and SBGR mix
(n  3). The ΔCt value expression from each sample was
calculated by normalizing with GAPDH or 18S rRNA. The
relative RNA amount of PAI1 were normalized to GAPDH,
and the relative RNA amount of Fibronectin, ColaI, and
aSMA were normalized to 18s rRNA. Primer specificity and
PCR process were verified by dissociation curve after PCR
reaction. The primer sequences for qPCR are described
separately in Supplementary Data.
Transmission Electron Microscopy and
Scanning Electron Microscopy
The prepared mPTD-BMP-7 was directly subjected to field
emission scanning electron microscope (Merlin, Zeiss). For
transmission electron microscopy (TEM), PDT-BMP-7 was
stained with 5% uranyl acetate for 10 min, and prepared for
micelle. 293A cells were treated with uranyl acetate–stained
mPTD-BMP-7 for various time periods, and the cells were
fixed with 2.5% glutaraldehyde. Cellular transduction of
mPTD-BMP-7 was monitored by TEM (JEM-1011, JEOL,
Peabody, MA, United States).
Histological Examination and
Immunohistochemistry
For histological and immunohistological examination, serial
paraffin sections were stained with H&E for routine
morphological observation. For immunohistochemical staining,
tissue sections in microslides were deparaffinized with xylene,
hydrated in serial dilution of alcohol, and immersed in 3%
hydrogen peroxide. The tissue sections were incubated with
protein blocking agent for 20 min at room temperature and
then incubated overnight at 4°C with primary antibody. After
washing with PBS three times, the sections were incubated with a
biotinylated secondary antibody (Immunotech) and streptavidin
conjugated to horseradish peroxidase for 20 min at room
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temperature. The chromogen was developed for 5 min with 3-
amino-9-ethylcarbazole (AEC) followed by counterstain with
Meyer’s hematoxylin.
Exosomal Purification
The 293 cells transiently transfected with flag-tagged FBN-1
expression vectors were treated with 500 ng of mPTD-BMP-7
in FBS-free DMEM (0.1% BSA) for a 16-h period. The culture
medium was centrifuged at 800 rpm for 3 min to remove cell
debris followed by 0.2 μm filtration. Two volumes of culture
medium were mixed with Exo-spin buffer (EX01, Cell
Guidance Systems). After 16 h, the mixture was centrifuged at
13,000 rpm for 60 min, and exosomal pellets were obtained.
Animal Experiments
All animal experiments were performed in accordance with the
Institutional Animal Care and Use Committee of the Yonsei
University and approved by the Animal Care Committee of the
Yonsei University College of Dentistry and National Cancer
Center Research Institute. Six-week old C57BL/6 mice were
anesthetized with intraperitoneal injection of tiletamine/
zolazepam (Zoletil®)-xylazine (Rompun®) mixture (1 mg/kg)
placed on a heating surgical pad. The mice underwent either a
sham operation or unilateral ureteral ligation with 4-0 suture silk
through an abdominal midline incision. A single dose of vehicle
(40 μl) or 20 μg mPTD-BMP-7 was injected into the urether above
the UUO ligation. Separately, UUO mice were administrated
20 μg of mPTD-BMP-7 or vehicle via tail vein every day for
1 week. The UUO mice were euthanized at day 7, and both
obstructed or unobstructed counterlateral kidney were harvested
for paraffin-embedded sections. Renal fibrosis was determined by
interstitial collagen deposition, immunostaining for α-smooth
muscle actin, and fibronectin.
For intra-arterial administration of mPTD-BMP-7, a female
12-week-age Yorkshire pig was used. The right femoral artery
access was used in all cases for pig. The left renal artery was
selected with a 5.0-F Kumpe catheter (Cook Inc.), and renal
angiography was obtained. Under the roadmap image, a
coaxial 2.4 F microcatheter (Progreat, Thrumo Medical) was
gently advanced into the main renal artery. Immediately after
the catheter insertion, total 100 ml of 0.9% saline mixed with
ICG-labeled mPTD-BMP-7 100 μg was infused into the left
renal artery over 2 h (50 ml/h) with infusion set (Sungshim
Medical). After 3 h, the pig was sacrificed to harvest both
kidneys for fluorescent imaging. Transduction of mPTD-
BMP-7 into the pig kidney was harvested for ex vivo
fluorescence imaging analysis and immunohistologic
analysis. Fluorescence images were acquired by VISQUE®
InVivo Smart (Vieworks, Anyang, South Korea) and were
analyzed by CleVue™ software (Vieworks, Anyang, South
Korea). Total signal intensity (*cm2) was normalized by
subtraction of control (counter lateral) signal intensity.
After the fluorescence imaging analysis, kidney specimens
were fixed in 10% formalin for paraffin sections. To
examine the intra-arterial injection of mPTD-BMP-7 in pig
UUO, unilateral urethral obstruction (left side only) was done
on the pig using laparoscopic approach under general
anesthesia. The next day, 100 μg of mPTD-BMP-7 was
administrated via renal artery for 2 h. After 7 days from
mPTD-BMP-7 treatment, the pig was euthanized, and both
kidneys were harvested for histologic analysis with H&E stain
and Masson’s Trichrome stain.
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